Good news for manufacturers of soap, bath and shower products is that growth has been solid, with sales increasing a hefty 18%, to about $5.4 billion, between 2008 and 2013, according to research firm Mintel.
With tens and possibly hundreds of billions of dollars in potential savings still snagged in a regulatory limbo, federal lawmakers and health industry stakeholders strongly urged the Food and Drug Administration last month to knock down the final barriers to review and approval of biosimilar drugs for marketing in the United States.
The pharmaceutical industry is back. Fueled by the launch of expensive, new biotech medicines, rising prices for both branded and generic drugs and a recent slowdown in branded-drug patent expirations and generic competition, the U.S. pharmaceutical market is staging a remarkable resurgence.
We didn’t go crazy making a lot of predictions for 2015. That’s because 2015 is the year so many of our past predictions will come true, as the forces of healthcare consumerism and mobile technology collide to forever change the way health care is purchased, consumed and delivered. Call it the Big Bang of retail health.